A Randomized Study of Two Dosing Regimens of Adagrasib in Patients With Previously Treated Non-Small Cell Lung Cancer With KRAS G12C Mutation
A Randomized Study of Two Dosing Regimens of Adagrasib in Patients With Previously Treated Non-Small Cell Lung Cancer With KRAS G12C Mutation
This study will evaluate the efficacy of two dosing regimens of adagrasib (600 mg BID versus 400 mg BID) in patients with NSCLC with KRAS G12C mutation.
CA239-0012 is a phase 2 study of adagrasib monotherapy in which patients are randomized between two dosing regimens. The study will evaluate the efficacy of two dosing regimens of adagrasib (600 mg BID without regard to food versus 400 mg BID with food) in patients with NSCLC with KRAS G12C mutation and who have received prior treatment with a platinum-based regimen and immune checkpoint inhibitor therapy.
Key Inclusion Criteria:
Key Exclusion Criteria:
Thessaloniki, North Aegean 552 36, Greece
Haidari - Athens, Pella 12462, Greece
Haifa, Tel Aviv 31048, Israel
Nis, Vojvodina 11000, Serbia
Kaohsuing City, Kaohsiung 833401, Taiwan
Muang, Chiang Mai 50200, Thailand
Istanbul, Samsun 34214, Turkey (Türkiye)
Istanbul, Samsun 34846, Turkey (Türkiye)